HSK-39297
- Generic Name
- HSK-39297
A Phase III Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT06799546
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
🇨🇳The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Long-term Safety and Tolerability of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 47
- Registration Number
- NCT06745622
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
A Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria（PNH）
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 45
- Registration Number
- NCT06561841
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
A Phase I Study to Assess the Safety,Tolerability, PK, PD, and Food Effect of HSK39297 in Healthy Subjects
- First Posted Date
- 2024-04-05
- Last Posted Date
- 2025-01-01
- Lead Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 96
- Registration Number
- NCT06350279
- Locations
- 🇨🇳
Beijing Tongren Hospital, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath